Nov 5, 4:26 PM ET
Amphastar reported third-quarter 2026 net revenues of $207.6 million, up 8% from $191.8 million a year earlier. GAAP net income was $37.8 million, or $0.87 per diluted share, compared with $17.4 million, or $0.37, in the prior-year quarter, which included a $23.1 million litigation provision. Gross margin fell to 48.0% from 51.4%, and the board authorized a $50 million increase to the share buyback program.
- Net revenues $207.6 million vs $191.8 million in Q3 2025, up 8%
- GAAP diluted EPS $0.87 vs $0.37; adjusted non-GAAP diluted EPS $1.14 vs $0.93
- Gross margin 48.0% vs 51.4%, mainly from lower average selling prices and higher remediation-related manufacturing costs
- Board authorized a $50 million increase to the share buyback program on November 4, 2026
Read the filing on SEC.gov ↗
Aug 6, 4:32 PM ET
Amphastar reported second-quarter 2026 net revenues of $183.9 million, up 5% from $174.4 million a year earlier, and gross margin rose to 50.8% from 49.6%. GAAP net income fell slightly to $30.3 million, though diluted EPS rose to $0.67 from $0.64 on a lower share count, and income from operations declined to $39.7 million from $42.2 million. Shareholders face a $100.0 million milestone payment to Eli Lilly due in the third quarter of 2026.
- Net revenues $183.9 million vs. $174.4 million a year earlier; glucagon sales fell 42% to $11.9 million
- GAAP net income $30.3 million, or $0.67 diluted EPS, vs. $31.0 million, or $0.64, in Q2 2025
- Adjusted non-GAAP net income $40.8 million, or $0.91 per diluted share, vs. $0.85 a year earlier
- BAQSIMI first annual net sales milestone of $175.0 million triggers a $100.0 million payment to Lilly due Q3 2026
Read the filing on SEC.gov ↗
Jul 13, 6:01 AM ET
Amphastar Pharmaceuticals increased its board from 10 to 11 seats on July 9, 2026, and appointed Anthony Pierce as a Class III director, effective immediately. The board deemed him independent under Nasdaq listing standards, and he has no committee assignments at this time.
- Board size increased from 10 to 11 directors; Pierce appointed effective immediately
- Pierce's term runs until the 2028 annual meeting of stockholders
- Annual cash retainer of $55,000, pro-rated for his start date
- Initial equity grant with aggregate grant date fair value of $300,000, split 50% restricted stock units and 50% stock options, vesting on the first anniversary
Read the filing on SEC.gov ↗
May 7, 4:22 PM ET
Amphastar reported first-quarter 2026 results with net revenues essentially flat at $171.2 million, up $643 thousand from a year earlier. GAAP net income fell to $6.4 million, or $0.14 per diluted share, from $25.3 million, or $0.51, as gross margin dropped to 41.1% from 50.0%. For shareholders, the flat sales and sharply lower profit point to weaker earnings, with the company citing higher cost of revenues and research and development spending.
- Net revenues were $171.2 million versus $170.5 million in Q1 2025, a 0% change.
- GAAP net income was $6.4 million ($0.14 per diluted share) versus $25.3 million ($0.51) a year earlier.
- Adjusted non-GAAP net income was $19.5 million ($0.42 per diluted share) versus $36.9 million ($0.74).
- BAQSIMI sales fell 15% to $32.4 million, and glucagon sales fell 56% to $9.2 million; cash flow from operations was $47.8 million.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.